```
=> e chain benjamin/au
E1          447       CHAIN B M/AU
E2            5       CHAIN B M */AU
E3           51  -->  CHAIN BENJAMIN/AU
E4          146       CHAIN BENJAMIN M/AU
E5            2       CHAIN BENJAMIN MICHAEL/AU
E6            7       CHAIN BENNY/AU
E7            1       CHAIN BM/AU
E8            2       CHAIN BRENT/AU
E9            9       CHAIN C/AU
E10           1       CHAIN C H/AU
E11           9       CHAIN C Y/AU
E12           2       CHAIN CASTRO T DE J/AU

=> s e1-e5 and (chimeric peptid?)
L1            2 ("CHAIN B M"/AU OR "CHAIN B M *"/AU OR "CHAIN BENJAMIN"/AU OR
                "CHAIN BENJAMIN M"/AU OR "CHAIN BENJAMIN MICHAEL"/AU) AND (CHIME
              RIC PEPTID?)

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2              2 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y


L2     ANSWER 1 OF 2  USPATFULL on STN
AN     2006:104446  USPATFULL
TI     Chimeric peptides as immunogens, antibodies thereto,
       and methods for immunization using chimeric peptides
       or antibodies
IN     Chain, Benjamin, London, UNITED KINGDOM
PI     US 2006088548      A1   20060427
AI     US 2000-731899     A1   20001208 (9)
PRAI   US 1999-169687P         19991208 (60)
DT     Utility
FS     APPLICATION
LREP   DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN   Number of Claims: 20
ECL    Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 1307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides a chimeric peptide or mixture
       of chimeric peptides that can be formulated as an
       immunizing composition and used in a method for immunization of a mammal
       against an internal peptide cleavage product derived from a precursor or
       mature protein, for which the peptide cleavage product and the precursor
       or mature protein are self molecules. The chimeric
       peptide or peptides have an end-specific B cell epitope from a
       naturally-occurring internal peptide cleavage product of a precursor or
       mature protein, as a free N- or C-terminus, fused with or without spacer
       residues to a T helper cell epitope derived from a living source
       different from that of the internal peptide cleavage product.

L2     ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN     2001:435132  CAPLUS
DN     135:60157
TI     Chimeric peptides as immunogens, antibodies thereto,
       and methods for immunization using chimeric peptides
       or antibodies
IN     Chain, Benjamin
PA     Mindset Biopharmaceuticals (Usa), Inc., USA
```

FAN.CNT 1

	PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042306		A2	20010614	WO 2000-US33203	20001208
	WO 2001042306		A3	20011101		

```
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
              HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
              LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
              YU, ZA, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

	PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
	CA 2393763		AA	20010614	CA 2000-2393763	20001208
	AU 2001027256		A5	20010618	AU 2001-27256	20001208
	AU 784925		B2	20060727		
	EP 1237930		A2	20020911	EP 2000-990195	20001208

```
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
```

	PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
	JP 2003516419		T2	20030513	JP 2001-543601	20001208
	US 2006088548		A1	20060427	US 2000-731899	20001208
	ZA 2002005032		A	20030922	ZA 2002-5032	20020621
PRAI	US 1999-169687P		P	19991208		
	WO 2000-US33203		W	20001208		

```
AB    The invention provides a chimeric peptide or mixture of
      chimeric peptides that can be formulated as an
      immunizing composition and used in a method for immunization of a mammal
      against an internal peptide cleavage product derived from a precursor or
      mature protein, for which the peptide cleavage product and the precursor
      or mature protein are self mols.  The chimeric peptide
      or peptides have an end-specific B cell epitope from a naturally-occurring
      internal peptide cleavage product of a precursor or mature protein, as a
      free N- or C- terminus, fused with or without spacer residues to a T
      helper cell epitope derived from a living source different from that of
      the internal peptide cleavage product.  The internal peptide cleavage
      product is an amyloid β peptide derived from cleavage of β
      amyloid precursor protein (βAPP); and the  chimeric
      peptide of T helper cell epitope is derived from tetanus toxoid,
      pertussis toxin, diphtheria toxin, measles virus F protein, etc.
      Antibodies or monoclonal antibodies raised with the chimeric
      peptides are useful for passive immunotherapy of diseases such as
      Alzheimer's disease.
```

```
=> s (chimeric peptide?) and (T helper cell epitope?) and amyloid
L3            7 (CHIMERIC PEPTIDE?) AND (T HELPER CELL EPITOPE?) AND AMYLOID

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4            7 DUP REM L3 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L4    ANSWER 1 OF 7  USPATFULL on STN
AN    2006:104446  USPATFULL
TI    Chimeric peptides as immunogens, antibodies thereto,
      and methods for immunization using chimeric peptides
      or antibodies
```

```
IN      Chain, Benjamin, London, UNITED KINGDOM
PI      US 2006088548      A1    20060427
AI      US 2000-731899     A1    20001208 (9)
PRAI    US 1999-169687P        19991208 (60)
DT      Utility
FS      APPLICATION
LREP    DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN    Number of Claims: 20
ECL     Exemplary Claim: 1
DRWN    2 Drawing Page(s)
LN.CNT 1307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB   The invention provides a chimeric peptide or mixture
        of chimeric peptides that can be formulated as an
        immunizing composition and used in a method for immunization of a mammal
        against an internal peptide cleavage product derived from a precursor or
        mature protein, for which the peptide cleavage product and the precursor
        or mature protein are self molecules. The chimeric
        peptide or peptides have an end-specific B cell epitope from a
        naturally-occurring internal peptide cleavage product of a precursor or
        mature protein, as a free N- or C-terminus, fused with or without spacer
        residues to a T helper cell
        epitope derived from a living source different from that of the
        internal peptide cleavage product.

```
L4    ANSWER 2 OF 7   USPATFULL on STN
AN      2005:188836  USPATFULL
TI      Novel method for down-regulation of amyloid
IN      Rasmussen, Peter Birk, Horsholm, DENMARK
        Jensen, Martin Roland, Horsholm, DENMARK
        Nielsen, Klaus Gregorius, Horsholm, DENMARK
        Koefoed, Peter, Horsholm, DENMARK
        Degan, Florence Dal, Horsholm, DENMARK
PI      US 2005163744      A1    20050728
AI      US 2004-783317     A1    20040220 (10)
RLI     Continuation-in-part of Ser. No. WO 2002-DK547, filed on 20 Aug 2002,
        UNKNOWN
PRAI    DK 2001-1231           20010820
        DK 2002-558            20020416
        US 2001-337543P        20011022 (60)
        US 2002-373027P        20020416 (60)
DT      Utility
FS      APPLICATION
LREP    FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY,
        10151, US
CLMN    Number of Claims: 51
ECL     Exemplary Claim: 1
DRWN    2 Drawing Page(s)
LN.CNT 3623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB   Disclosed are novel methods for combatting diseases characterized by
        deposition of amyloid. The methods generally rely on
        immunization against amyloid precursor protien (APP) or beta
        amyloid (Aβ). Immunization is preferably effected by
        administration of analogues of autologous APP or Aβ, said analogues
        being capable of inducing antibody production against the autologous
        amyloidogenic polypeptides. Especially preferred as an immunogen is
        autologous Aβ which has been modified by introduction of one single
        or a few foreign, immunodominant and promiscuous T-cell epitopes. Also
        disclosed are nucleic acid vaccination against APP or Aβ and
        vaccination using live vaccines as well as methods and means useful for
        the vaccination. Such methods and means include methods for the
        preparation of analogues and pharmaceutical formulations, as well as
        nucleic acid fragments, vectors, transformed cells, polypeptides and

pharmaceutical formulations.

L4   ANSWER 3 OF 7   USPATFULL on STN
AN   2005:69661   USPATFULL
TI   Prevention and treatment of amyloidogenic disease
IN   Schenk, Dale B., Burlingame, CA, UNITED STATES
        Bard, Frederique, Pacifica, CA, UNITED STATES
        Yednock, Theodore, Forest Knolls, CA, UNITED STATES
PA   Neuralab Ltd (U.S. corporation)
PI   US 2005059802   A1   20050317
AI   US 2004-777792   A1   20040211 (10)
RLI   Continuation of Ser. No. US 2000-723544, filed on 28 Nov 2000, ABANDONED
        Continuation of Ser. No. US 2000-580018, filed on 26 May 2000, GRANTED,
        Pat. No. US 6761888 Continuation-in-part of Ser. No. US 1999-322289,
        filed on 28 May 1999, PENDING Continuation-in-part of Ser. No. US
        1998-201430, filed on 30 Nov 1998, GRANTED, Pat. No. US 6787523
PRAI   US 1998-80970P   19980407 (60)
DT   Utility
FS   APPLICATION
LREP   TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
        FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN   Number of Claims: 51
ECL   Exemplary Claim: CLM-01-68
DRWN   18 Drawing Page(s)
LN.CNT 4942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The invention provides improved agents and methods for treatment of
        diseases associated with amyloid deposits of Aβ in the
        brain of a patient. Such methods entail administering agents that induce
        a beneficial immunogenic response against the amyloid deposit.
        The methods are useful for prophylactic and therapeutic treatment of
        Alzheimer's disease. Preferred agents including N-terminal fragments of
        Aβ and antibodies binding to the same.

L4   ANSWER 4 OF 7   USPATFULL on STN
AN   2004:313942   USPATFULL
TI   Immunogenic peptide composition for the prevention and treatment of
        Alzheimer's Disease
IN   Wang, Chang Yi, Harbor, NY, UNITED STATES
PI   US 2004247612   A1   20041209
AI   US 2004-861614   A1   20040604 (10)
RLI   Division of Ser. No. US 2001-865294, filed on 25 May 2001, PENDING
DT   Utility
FS   APPLICATION
LREP   MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053
CLMN   Number of Claims: 76
ECL   Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 1731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention relates to a composition comprsing a peptide
        immunogen useful for the prevention and treatment of Alzheimer's
        Disease. More particularly, the peptide immunogen comprises a main
        functional/regulatory site, an N-terminal fragment of Amyloid
        β (Aβ) peptide linked to a helper T cell epitope (Th) having
        multiple class II binding motifs. The peptide immunogen elicit a
        site-directed immune response against the main functional/regulatory
        site of the Aβ peptide and generate antibodies, which are highly
        cross-reactive to the soluble Aβ.sub.1-42 peptide and the
        amyloid plaques formed in the brain of Alzheimer's Disease
        patients. The antibodies elicited being cross reactive to the soluble
        Aβ.sub.1-42 peptide, promote fibril disaggregation and inhibit
        fibrillar aggregation leading to immunoneutralization of the "soluble
        Aβ-derived toxins"; and being cross-reactive to the amyloid

plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.

L4   ANSWER 5 OF 7   USPATFULL on STN
AN   2003:225306   USPATFULL
TI   Novel method for down-regulation of amyloid
IN   Rasmussen, Peter Birk, Horsholm, DENMARK
       Jensen, Martin Roland, Horsholm, DENMARK
       Nielsen, Klaus Gregorius, Horsholm, DENMARK
       Koefoed, Peter, Horsholm, DENMARK
       Degan, Florence Dal, Horsholm, DENMARK
PI   US 2003157117   A1   20030821
AI   US 2002-223809   A1   20020820 (10)
PRAI   DK 2001-1231   20010820
       DK 2002-58   20020416
       US 2001-337543P   20011022 (60)
       US 2002-373027P   20020416 (60)
DT   Utility
FS   APPLICATION
LREP   FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151
CLMN   Number of Claims: 42
ECL   Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 3681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Disclosed are novel methods for combatting diseases characterized by
       deposition of amyloid. The methods generally rely on
       immunization against amyloid precursor protien (APP) or beta
       amyloid (Aβ). Immunization is preferably effected by
       administration of analogues of autologous APP or Aβ, said analogues
       being capable of inducing antibody production against the autologous
       amyloidogenic polypeptides. Especially preferred as an immunogen is
       autologous Aβ which has been modified by introduction of one single
       or a few foreign, immunodominant and promiscuous T-cell epitopes. Also
       disclosed are nucleic acid vaccination against APP or Aβ and
       vaccination using live vaccines as well as methods and means useful for
       the vaccination. Such methods and means include methods for the
       preparation of analogues and pharmaceutical formulations, as well as
       nucleic acid fragments, vectors, transformed cells, polypeptides and
       pharmaceutical formulations.

L4   ANSWER 6 OF 7   USPATFULL on STN
AN   2003:99221   USPATFULL
TI   Immunogenic peptide composition for the prevention and treatment of
       Altzheimers Disease
IN   Wang, Chang Yi, Cold Spring Harbor, NY, UNITED STATES
PI   US 2003068325   A1   20030410
       US 6906169   B2   20050614
AI   US 2001-865294   A1   20010525 (9)
DT   Utility
FS   APPLICATION
LREP   Maria C.H. Lin, Morgan & Finnegan L.L.P, 345 Park Avenue, New York, NY,
       10154-0053
CLMN   Number of Claims: 80
ECL   Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 2076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention relates to a composition comprsing a peptide
       immunogen useful for the prevention and treatment of Alzheimer's
       Disease. More particularly, the peptide immunogen comprises a main
       functional/regulatory site, an N-terminal fragment of Amyloid
       β (Aβ) peptide linked to a helper T cell epitope (Th) having

multiple class II MHC binding motifs. The peptide immunogen elicit a
site-directed immune response against the main functional/regulatory
site of the Aβ peptide and generate antibodies, which are highly
cross-reactive to the soluble Aβ.sub.1-42 peptide and the
amyloid plaques formed in the brain of Alzheimer's Disease
patients. The antibodies elicited being cross reactive to the soluble
Aβ.sub.1-42 peptide, promote fibril disaggregation and inhibit
fibrillar aggregation leading to immunoneutralization of the "soluble
Aβ-derived toxins"; and being cross-reactive to the amyloid
plaques, accelerate the clearance of these plaques from the brain. Thus,
the composition of the invention comprising the peptide immunogen is
useful for the prevention and treatment of Alzheimer's Disease.

```
L4     ANSWER 7 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
AN     2001:435132  CAPLUS
DN     135:60157
TI     Chimeric peptides as immunogens, antibodies thereto,
       and methods for immunization using chimeric peptides
       or antibodies
IN     Chain, Benjamin
PA     Mindset Biopharmaceuticals (Usa), Inc., USA
SO     PCT Int. Appl., 47 pp.
       CODEN: PIXXD2
DT     Patent
LA     English
FAN.CNT 1
       PATENT NO.          KIND   DATE        APPLICATION NO.           DATE
       ---------------     ----   --------    --------------------      --------
PI     WO 2001042306       A2     20010614    WO 2000-US33203           20001208
       WO 2001042306       A3     20011101
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
              HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
              LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
              YU, ZA, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
       CA 2393763          AA     20010614    CA 2000-2393763          20001208
       AU 2001027256       A5     20010618    AU 2001-27256            20001208
       AU 784925           B2     20060727
       EP 1237930          A2     20020911    EP 2000-990195           20001208
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
       JP 2003516419       T2     20030513    JP 2001-543601           20001208
       US 2006088548       A1     20060427    US 2000-731899           20001208
       ZA 2002005032       A      20030922    ZA 2002-5032             20020621
PRAI   US 1999-169687P     P      19991208
       WO 2000-US33203     W      20001208
AB     The invention provides a chimeric peptide or mixture of
       chimeric peptides that can be formulated as an
       immunizing composition and used in a method for immunization of a mammal
       against an internal peptide cleavage product derived from a precursor or
       mature protein, for which the peptide cleavage product and the precursor
       or mature protein are self mols.  The chimeric peptide
       or peptides have an end-specific B cell epitope from a naturally-occurring
       internal peptide cleavage product of a precursor or mature protein, as a
       free N- or C- terminus, fused with or without spacer residues to a
       T helper cell epitope derived from a
       living source different from that of the internal peptide cleavage
       product.  The internal peptide cleavage product is an amyloid
       β peptide derived from cleavage of β   amyloid precursor
       protein (βAPP); and the  chimeric peptide of
```

T helper cell epitope is derived
from tetanus toxoid, pertussis toxin, diphtheria toxin, measles virus F
protein, etc. Antibodies or monoclonal antibodies raised with the
chimeric peptides are useful for passive immunotherapy
of diseases such as Alzheimer's disease.